Please login to the form below
larotrectinib
This page shows the latest larotrectinib news and features for those working in and with pharma, biotech and healthcare.
Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies
To date, Vitrakvi (larotrectinib) &Rozlytrek (entrectinib) are the only ‘pure’ TA products to receive conditional EMA approval and accelerated FDA approval for NTRK positive tumours.
Latest news
-
Immuno-oncology, personalised medicine continues to drive pharma sector
A recent example of this issue is Bayer’s tumour-agnostic drug Vitrakvi (larotrectinib), which targets all solid tumours that display a NTRK gene fusion regardless of cancer type, but was
-
NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
In a blow to Bayer, NICE also said in the statement that Roche’s Vitrakvi (larotrectinib) rival Rozlytrek (entrectinib) could instead become the first histology independent treatment to be made available ... In its draft guidance, the NICE committee
-
Lilly expands dermatology portfolio with $1.1bn Dermira deal
From that deal, Lilly gained TRK inhibitor Vikrakvi (larotrectinib), a targeted cancer drug for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours with a neurotrophic
-
Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval
Will likely face competition soon from rival Rozlytrek. Bayer’s Vitrakvi (larotrectinib) has become the first tumour-agnostic drug in Europe to be approved for the treatment of cancer.
-
Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO
The company has just picked up a new approval for targeted cancer drug Rozlytrek(entrectinib), a rival to Bayer’s Vitrakvi (larotrectinib), and for anti-CD79b antibody drug conjugate Polivy (polatuzumab
Immuno-oncology, personalised medicine continues to drive pharma sector
NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
Lilly expands dermatology portfolio with $1.1bn Dermira deal
Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval
Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO
More from news
Approximately 2 fully matching, plus 23 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
Vitrakvi(larotrectinib) gained FDA approval in late November to treat any solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, which causes the production of TRK, a family ... In Europe, a marketing application for
-
Cancer immunotherapy: What's on the horizon?
also extending to targeted cancer drugs, with Loxo Oncology and Bayer’s larotrectinib filed for TRK gene fusion tumours and due for an FDA verdict in November.
Drug launches to watch in 2019
Cancer immunotherapy: What's on the horizon?
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital account director
-
Competitive
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Midweight-Senior Creative
-
Competitive Salary Offered
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
- CONGREGO™ IS NOW MULTI-PLATFORM
- Onyx Health Marks Record Growth with Six New Appointments
- FDA expands use of COVID-19 antibody cocktail
- New European supply deals show Pfizer and Moderna have increased COVID-19 vaccine prices
- Ipsen’s spending spree bolsters neurology pipeline
- AMICULUM® launches Cence, a new specialist publications agency
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients
- Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
- Eylea set to challenge Lucentis in UK after NICE recommendation
- Onyx Health Launch Creative Studio After Record Year
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- Guide
- How to embrace behavioural science principles in healthcare MR...
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
